CD274 and neoplasm: Currently, there are several biomarkers that can predict the responsiveness of immunotherapy, such as the mRNA level of Programmed cell death 1 ligand 1(PD-L1), tumor mutation burden (TMB), microsatellite instability (MSI), and molecular subtypes (11–14).